4.3 Article

Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway

Journal

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
Volume 100, Issue 1, Pages 68-77

Publisher

CANADIAN SCIENCE PUBLISHING
DOI: 10.1139/cjpp-2021-0299

Keywords

amlexanox; beta-arrestins; biased agonists; carvedilol; insulin resistance; paroxetine

Ask authors/readers for more resources

This study aimed to investigate the acute and chronic effects of carvedilol on insulin resistance in high-fructose, high-fat diet fed mice and the implication of the beta-arrestin2 pathway. The results showed that carvedilol acutely reduced fasting blood glucose levels and chronic administration significantly ameliorated insulin resistance and dyslipidemia in the mice. The insulin sensitizing effects of carvedilol are highly correlated with the up regulation of the beta-arrestin2 pathway.
We aimed to investigate the acute and chronic effects of carvedilol on insulin resistance in high-fructose, high-fat diet (HFrHFD) - fed mice and the implication of the beta-anrestin2 pathway. The acute effect of carvedilol (10 mg/kg, i.p.) on glucose tolerance and hepatic lipid signaling in normal and insulin resistant mice was investigated. Then, the chronic effect of carvedilol on insulin resistance and dyslipidemia in HFrHFD-fed mice was examined. Changes in beta-arrestin2 and its downstream signals in liver, skeletal muscle, and adipose tissue were measured. This involved measuring phosphatidylinositol 4,5-bisphosphate (PIP2) and diacylglycerol (DAG) levels and protein kinase B (AKT) activity. Carvedilol acutely reduced fasting blood glucose levels in both normal and insulin resistant mice without significantly affecting the glucose tolerance. These acute effects were associated with increased hepatic PIP2 but decreased hepatic DAG levels. Chronic administration of carvedilol significantly ameliorated insulin resistance and dyslipidemia in HFrHFD-fed mice. These chronic effects were associated with increased beta-arrestin2, PIP2, and AKT activity levels but decreased DAG levels in the classical insulin target tissues. In conclusion, carvedilol acutely maintains glucose homeostasis and chronically ameliorates insulin resistance and dyslipidemia in HFrHFD-fed mice. The insulin sensitizing effects of carvedilol are highly correlated with the up regulation of beta-arrestin2 pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available